Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 905-459-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
DIPB was negative in Ames and Chromosomal aberrations in vitro. Additionally the 1,3-DIPB isomer was considered to be non-mutagenic in the in vitro mammalian cell gene mutation assay (thymidine kinase locus) in mouse lymphoma L5178Y cells.
Link to relevant study records
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Deviations:
- no
- Principles of method if other than guideline:
- Study performed according to Guidelines for Screening Mutagenicity Testing of Chemicals (Japan) and OECD Guideline No. 473
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian chromosome aberration test
- Species / strain / cell type:
- other: Chinese hamster lung cells (CHL/IU)
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 mix from rat liver (induction with phenobarbital and 5,6-benzoflavone)
- Test concentrations with justification for top dose:
- -S9 mix (continuous treatment): 0, 0.0038, 0.0075 and 0.015 mg/mL
-S9 mix (short-term treatment): 0, 0.0019, 0.0038 and 0.0075 mg/mL
+S9 mix (short-term treatment): 0, 0.03, 0.06 and 0.12 mg/mL - Vehicle / solvent:
- Acetone
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- Acetone
- Positive controls:
- yes
- Remarks:
- see below
- Positive control substance:
- other: see below
- Details on test system and experimental conditions:
- Positive controls:
-S9 mix: Mitomycin C
+S9 mix: Cyclophosphamide
Continuous treatment: 24 and 48 hrs
Short-term treatment: 6 hrs
2 plates/test - Evaluation criteria:
- according to OECD Guideline No. 473
- Statistics:
- Yes
- Species / strain:
- other: Chinese hamster lung cells (CHL/IU)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- See Additional information on results
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- Cytotoxicity:
Short-term treatment: >= 0.015 mg/mL
Continuous treatment: >= 0.03 mg/mL - Conclusions:
- The TS caused no chromosomal aberrations or polyploidy in Chinese hamster lung cells (CHL/IU), with or without an exogenous metabolic activation system.
- Executive summary:
The TS was tested in an in vitro mammalian chromosome aberration test with Chinese hamster lung cells (CHL/IU) according to OECD Guideline No. 473.
The test concentrations were as follows:
-S9 mix (continuous treatment; 24 or 48 hrs): 0, 0.0038, 0.0075 and 0.015 mg/mL
-S9 mix (short-term treatment; 6 hrs): 0, 0.0019, 0.0038 and 0.0075 mg/mL
+S9 mix (short-term treatment; 6 hrs): 0, 0.03, 0.06 and 0.12 mg/mL.
The TS caused no chromosomal aberrations or polyploidy in Chinese hamster lung cells (CHL/IU), with or without an exogenous metabolic activation system.
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 472 (Genetic Toxicology: Escherichia coli, Reverse Mutation Assay)
- Deviations:
- no
- Principles of method if other than guideline:
- Pre-incubation method; Study performed according to Guidelines for Screening Toxicity Testing of Chemicals (Japan) and OECD Guidelines No. 471 and 472
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Species / strain / cell type:
- E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 mix from rat liver (induction with phenobarbital and 5,6-benzoflavone)
- Test concentrations with justification for top dose:
- -S9 mix:
0, 0.195, 0.391, 0.781, 1.56, 3.13 and 6.25 ug/plate (TA 1537)
0, 0.781 - 50.0 ug/plate (TA 100, TA 1535, TA 98 [Test 1])
0, 0.391 - 12.5 ug/plate (TA 1535 [Test 2])
0, 0.781 - 25.0 ug/plate (TA 100, TA98 [Test 2])
0, 156 - 5000 ug/plate (E. coli WP2 uvrA)
+S9 mix:
0, 6.25 - 200 ug/plate (TA 100, TA 1535, TA 98, TA 1537)
0, 19.5 - 625 ug/plate (E. coli WP2 uvrA) - Vehicle / solvent:
- DMSO
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- Positive controls:
- yes
- Remarks:
- see below
- Positive control substance:
- other: see below
- Details on test system and experimental conditions:
- Positive controls:
-S9 mix:
TA 100, TA 98, E. coli WP2 uvrA: 2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide
TA 1535: Sodium azide
TA 1537: 9-aminoacridine
+S9 mix:
All strains: 2-aminoanthracene - Evaluation criteria:
- according to OECD Guidelines No. 471 and 472
- Statistics:
- Yes
- Species / strain:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- see below
- Vehicle controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- see below
- Vehicle controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- Cytotoxicity:
-S9 mix:
TA 100: >= 12.5 ug/plate
TA 1535: >= 6.25 ug/plate
TA 98: >= 12.5 ug/plate
TA 1537: >= 6.25 ug/plate
E. coli: 5000 ug/plate
+S9 mix:
TA 100, TA 1535, TA 98 and TA 1537: >= 100 ug/plate
E. coli: 625 ug/plate - Conclusions:
- The TS was not mutagenic in Salmonella typhimurium TA 100, TA 1535, TA 98, TA 1537 and Escherichia coli WP2 uvrA, with or without an exogenous metabolic activation system.
- Executive summary:
S. typhimurium TA 1535, TA 1537, TA 98 and TA 100 as well as E. coli WP2 uvr A were tested in a pre-incubation assay performed according to OECD Guidelines No. 471 and 472.
The test concentrations were given as follows:
-S9 mix:
0, 0.195, 0.391, 0.781, 1.56, 3.13 and 6.25 ug/plate (TA 1537)
0, 0.781 - 50.0 ug/plate (TA 100, TA 1535, TA 98 [Test 1])
0, 0.391 - 12.5 ug/plate (TA 1535 [Test 2])
0, 0.781 - 25.0 ug/plate (TA 100, TA98 [Test 2])
0, 156 - 5000 ug/plate (E. coli WP2 uvrA)
+S9 mix:
0, 6.25 - 200 ug/plate (TA 100, TA 1535, TA 98, TA 1537)
0, 19.5 - 625 ug/plate (E. coli WP2 uvrA).
Cytotoxic effects were seen at the following concentrations:
-S9 mix:
TA 100: >= 12.5 ug/plate
TA 1535: >= 6.25 ug/plate
TA 98: >= 12.5 ug/plate
TA 1537: >= 6.25 ug/plate
E. coli: 5000 ug/plate
+S9 mix:
TA 100, TA 1535, TA 98 and TA 1537: >= 100 ug/plate
E. coli: 625 ug/plate.
The TS was not mutagenic in Salmonella typhimurium TA 100, TA 1535, TA 98, TA 1537 and Escherichia coli WP2 uvrA, with or without an exogenous metabolic activation system.
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- from 12 Semtember 2012 to 3 January 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- read-across: supporting information
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- mammalian cell gene mutation assay
- Target gene:
- thymidine kinase
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Details on mammalian cell type (if applicable):
- Mouse Lymphoma L5178Y cells have been used successfully in in vitro experiments for many years. These cells are characterised by their high proliferation rate (10-12 h doubling time of the BSL BIOSERVICE stock cultures) and their cloning efficiency, usually more than 50%. The cells obtain a near diploid karyotype (40 ± 2 chromosomes). They are heterozygous at the Thymidine Kinase (TK) locus in order to detect mutation events at the TK-locus. To prevent high backgrounds arising from spontaneous mutation, cells lacking TK can be eliminated by culturing cells in RPMI 1640 supplemented with: 9.0 ug/mL hypoxanthine
15.0 ug/mL thymidine
22.5 ug/mL glycine
0.1 ug/mL methotrexate
The cells are resuspended in medium without methotrexate but thymidine, hypoxanthine and glycine for 1-3 days. Large stock cultures of the cleansed L5178Y cell line are stored over liquid nitrogen (vapour phase) in the cell bank of BSL BIOSERVICE. This allows the repeated use of the same cell batch in experiments. Each cell batch is routinely checked for mycoplasma infection.
Thawed stock cultures are maintained in plastic culture flasks in RPMI 1640 complete medium and subcultured three times per week. - Additional strain / cell type characteristics:
- not specified
- Metabolic activation:
- with and without
- Metabolic activation system:
- mammalian microsomal fraction S9 homogenate
- Test concentrations with justification for top dose:
- The toxicity of the test item was determined in pre-experiments up to a maximum concentration of 9. 6 mM.
Reason:
For the solubility experiment and for pre-experiment I the correction factor of 1.042 was not applied to correct for 100% purity of the test item. Due to this in the solubility experiment and in pre-experiment I the maximum concentration was 9.6 mM instead of 10 mM. However, both experiments still provided the information required and results were used for evaluation of solubility and cytotoxicity of the test item. - Vehicle / solvent:
- ethanol (0.5% v/v)
- Untreated negative controls:
- yes
- Remarks:
- treatment medium
- Negative solvent / vehicle controls:
- yes
- Remarks:
- 0.5% v/v ethanol
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- benzo(a)pyrene
- ethylmethanesulphonate
- methylmethanesulfonate
- Details on test system and experimental conditions:
- Pre-Experiment for Toxicity
The toxicity of the test item was determined in pre-experiments up to a maximum concentration of9.6 mM. For experiment I six concentrations [0.19, 0.48, 2.4, 4.8, 7.2 and 9.6 mM] were tested with and without metabolic activation. Due to high cytotoxicity of the test item only dose groups up to 2.4 mM are reported. For the 24 h long~terrn exposure assay (experiment II, without metabolic activation) eight concentrations [0.0048, 0.0096, 0.019, 0.048, 0.096, 0.48, 0.96, 1.92 mM] were tested. Due to high cytotoxicity of the test item only dose groups up to 0.48 mM are reported. The experimental conditions in these pre-experiments were the same as described below under "experimental performance".
Exposure Concentrations
The selection of the concentrations used in the main experiments was based on data from the pre-experiment. In experiment I 3.00 mM (with metabolic activation) and 0.50 mM (without metabolic activation) were selected as the highest concentrations. In experiment II 0.40 mM (with metabolic activation) and 0.20 mM (without metabolic activation) were selected as the highest concentrations. Experiment I with and without metabolic activation and experiment II with metabolic activation were performed as 4 h short-term exposure assay. Experiment II without metabolic activation was performed
as a 24 h long-term exposure assay. The test item was investigated at the following concentrations:
Experiment I with metabolic activation:
0.1 0, 0.20, 0.40, 0.80, 1.20, 1.60, 2.00, 2.40, 2.80 and 3.00 mM
Experiment I without metabolic activation:
0.05, 0.08, 0.10, 0.15, 0.20, 0.30, 0.40 and 0.50 mM
Experiment II with metabolic activation:
0.01, 0.02, 0.05, 0.10, 0.20, 0.30, 0.35 and 0.40 mM
Experiment II without metabolic activation:
0.002, 0.005, 0.01, 0.02, 0.05, 0.10, 0.15 and 0.20 mM
According to OECD Guidelines at least 8 concentrations of the test item were set up in the experiments with and without metabolic activation.
Cell Culture Media
For preparation of the different media horse serum (HS) was heat-inactivated for 30 min. at 56 degrees C prior usage.
Complete Culture Medium (RPMI 1640 medium) supplemented with:
10 % Horse serum (HS)
1 00 U/1 00 ug/mL penicillin/streptomycin
1 mM sodium pyruvate
2 mM L-glutamine
25 mM HEPES
2.5 ug/mL amphotericin B
Treatment Medium (RPMI 1640 medium) supplemented with:
5% HS (in case of short-term exposure)
7.5 % HS (in case of long-term exposure)
100 U/100 J.lg/mL penicillin/streptomycin
1 mM sodium pyruvate
2 mM L-glutamine
25 mM HEPES
2.5 ug/mL amphotericin B
Selective Medium (RPMI 1640 medium) supplemented with:
20% HS
100 U/100 ug/mL penicillin/streptomycin
1 mM sodium pyruvate
2 mM L-glutamate
25 mM HEPES
2.5 1-tg/mL amphotericin
5 ug/mL TFT - Evaluation criteria:
- Acceptability of the Assay
A mutation assay is considered acceptable if it meets the criteria mentioned in current international guidelines and the current recommendations of the IWGT (11, 12, 13, 14, 15):
- At least three out of four 96-well plates from the TFT resistance-testing portion of the experiment are scorable.
- The cloning efficiency of the negative and/or solvent controls is in the range 65%-120%.
- The spontaneous mutant frequency in the negative and/or solvent controls is in the range 50-170 mutants per 1 06 cells
- The cell number of the negative/solvent controls should undergo 8-32 fold increase during a 2 day growth period (short-term treatment) or 32-1 80 fold increase during a 3 day growth period (long-term treatment).
- The clastogenic positive controls (MMS and B[a]P) have to produce an induced mutant frequency (total mutant frequency minus concurrent negative control mutant frequency) of at least 300 mutants per 106 cells with at least 40% of the colonies being small colonies or with an induced small
colony mutant frequency of at least 150 mutants per 106 cells The RTG must be greater than 10%.
Evaluation of Results
The test item is considered mutagenic if following criteria are met (13, 14, 15):
The induced mutant frequency meets or exceeds the Global Evaluation factor (GEF) of 126 mutants per 106 celts
A dose-dependent increase in mutant frequency is detected.
Besides, combined with. a positive effect in the mutant frequency, an increased occurrence of small colonies (~40% of total colonies) is an indication for potential clastogenic effects and/or chromosomal aberrations.
According to the OECD guideline, the biological relevance is considered first for the interpretation of results. Statistical methods might be used as an aid in evaluation the test result. A test item is considered to be negative if the induced mutant frequency is below the GEF and the trend test is negative. - Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- above 2.4 mM
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Data on pH: pH-value was winthin the physiological range
- Precipitation and time of the determination: noted in the pre-experiment I with and without metabolic activation at a concentration of 2.4 mM and higher. In the experiments I and II with and without metabolic activation and in the pre-experiment II witohut metabolic activiation no precipitation was noted.
STUDY RESULTS
- Concurrent vehicle negative and positive control data
Gene mutation tests in mammalian cells:
- Results from cytotoxicity measurements:
Growth inhibition was observed in experiment I and II with and without metabolic activation.
In experiment I with metabolic activation, the relative total growth (RTG) was 12.3% for the highest concentration (3.00 mM) evaluated. The highest concentration evaluated without metabolic activiation was 0.50 mM with a RTG of 21.5%. In experiment II with metabolic activation the RTG was 15.7% for the highest concentration (0.40 mM) evaluation. The highest concentration evaluated without metabolic activation was 0.20 mM with a RTG of 7.9%.
- Genotoxicity results:
In experiment I and II no biologically relevant increase of mutants was found after treatment with the test item (with and without metabolic activiation). The Global Evaluation Factor (GEF) was not exceeded by the induced mutant freqency at any concentration.
No dose-response relationship was observed.
In experiment I and II colony sizing showed no clastogenic effects induced by the the test item under the experimental conditions (with and without metabolic activiation).
EMS, MMS and B[a]P were used as positive controls and showed distinct and biologically relevant effects in mutation freqency. Additionally, MMS and B[a]P significantly increased the number of small colonies, thus proving the efficiency of the test system to indicate potential clastogenic effects. - Conclusions:
- Eastman ™ meta-Diisopropylbenzene is considered to be non-mutagenic in the in vitro mammalian cell gene mutation assay (thymidine kinase locus)
in mouse lymphoma L5178Y cells. - Executive summary:
The test item Eastman ™ meta-Diisopropylbenzene was assessed for its potential to induce mutations at the mouse lymphoma thymidine kinase locus using the cell line L5178Y. The selection of the concentrations used in the main experiments was based on data from a pre-experiments. The test item was investigated at the following concentrations: Experiment I with metabolic activation: 0.10, 0.20, 0.40, 0.80, 1.20, 1.60, 2.00, 2.40, 2.80 and 3.00 mM and without metabolic activation: 0.05, 0.08, 0.10, 0.15, 0.20, 0.30, 0.40 and 0.50 mM Experiment II with metabolic activation: 0.01, 0.02, 0.05, 0.1 0, 0.20, 0.30, 0.35 and 0.40 mM and without metabolic activation: 0.002, 0.005, 0.01, 0.02, 0.05, 0.10, 0.15 and 0.20 mM Precipitation of the test item was noted in the pre-experiment I with and without metabolic activation at a concentration of 2.4 mM and higher. In the experiments I and II with and without metabolic activation and in the pre-experiment II without metabolic activation no precipitation was noted. Growth inhibition was observed in experiment I and II with and without metabolic activation. In experiment I with metabolic activation the relative total growth (RTG) was 12.3% for the highest concentration (3.00 mM) evaluated. The highest concentration evaluated without metabolic activation was 0.50 mM with a RTG of21.5%. In experiment II with metabolic activation the relative total growth (RTG) was 15.7% for the highest concentration (0.40 mM) evaluated. The highest concentration evaluated without metabolic activation was 0.20 mM with a RTG of 7.9%. In experiment I and II no biologically relevant increase of mutants was found after treatment with the test item (with and without metabolic activation). The Global Evaluation Factor (GEF; defined as the mean of the negative/vehicle mutant frequency plus one standard deviation; data gathered from ten laboratories) was not exceeded by the induced mutant frequency at any concentration. No dose-response relationship was observed. Additionally, in experiment I and II colony sizing showed no clastogenic effects induced by the test item under the experimental conditions (with and without metabolic activation). EMS, MMS and B[a]P were used as positive controls and showed distinct and biologically relevant effects in mutation frequency. Additionally, MMS and B[a]P significantly increased the number of small colonies, thus proving the efficiency of the test system to indicate potential clastogenic effects.
Referenceopen allclose all
see attachement
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
S. typhimurium TA 1535, TA 1537, TA 98 and TA 100 as well as E. coli WP2 uvr A were tested in a pre-incubation assay performed according to OECD Guidelines No. 471 and 472.
The test concentrations were between 0 and 200 µg/plate (limited by cytotoxic effects) in S. typhimurium and up to 5000 µg/plate in E. coli.
DIPB was not mutagenic in Salmonella typhimurium TA 100, TA 1535, TA 98, TA 1537 and Escherichia coli WP2 uvrA, with or without an exogenous metabolic activation system.
DIPB was tested in an in vitro mammalian chromosome aberration test with Chinese hamster lung cells (CHL/IU) according to OECD Guideline No. 473.
The test concentrations were as follows:
-S9 mix (continuous treatment; 24 or 48 hrs): 0, 0.0038, 0.0075 and 0.015 mg/mL
-S9 mix (short-term treatment; 6 hrs): 0, 0.0019, 0.0038 and 0.0075 mg/mL
+S9 mix (short-term treatment; 6 hrs): 0, 0.03, 0.06 and 0.12 mg/mL.
DIPB caused no chromosomal aberrations or polyploidy in Chinese hamster lung cells (CHL/IU), with or without an exogenous metabolic activation system.
Additional results with the 1,3-DIPB isomer (pure):
The test item Eastman ™ meta-Diisopropylbenzene was assessed for its potential to induce mutations at the mouse lymphoma thymidine kinase locus using the cell line L5178Y. The test item was investigated at the following concentrations:
- Experiment I with metabolic activation: 0.10, 0.20, 0.40, 0.80, 1.20, 1.60, 2.00, 2.40, 2.80 and 3.00 mM and without metabolic activation: 0.05, 0.08, 0.10, 0.15, 0.20, 0.30, 0.40 and 0.50 mM
Experiment II with metabolic activation: 0.01, 0.02, 0.05, 0.1 0, 0.20, 0.30, 0.35 and 0.40 mM and without metabolic activation: 0.002, 0.005, 0.01, 0.02, 0.05, 0.10, 0.15 and 0.20 mM
In experiment I and II no biologically relevant increase of mutants was found after treatment with the test item (with and without metabolic activation). No dose-response relationship was observed. Additionally, in experiment I and II colony sizing showed no clastogenic effects induced by the test item under the experimental conditions (with and without metabolic activation). EMS, MMS and B[a]P were used as positive controls and showed distinct and biologically relevant effects in mutation frequency. Additionally, MMS and B[a]P significantly increased the number of small colonies, thus proving the efficiency of the test system to indicate potential clastogenic effects.
Justification for classification or non-classification
According to CLP (EC regulation 1272/2008) no classification of DIPB for germ cell mutagenicity is required. Based on the available key studies, there is no mutagenic potential in vitro.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.